Related Experiment Video
Updated: Jul 14, 2026
12:27
A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
Published on: June 8, 2022
Transcriptomic Profiling and Drug Repurposing Identify Fostamatinib as a Candidate Therapeutic Agent for IgG4-Related
Motohisa Yamamoto1, Ryuta Kamekura2, Masaaki Uehara1
1Department of Rheumatology, Allergy and Clinical Immunology, IMSUT Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Modern Rheumatology
|July 13, 2026
Summary
Fostamatinib shows promise for treating IgG4-related sialadenitis, a rare IgG4-related disease. This study identified fostamatinib as a potential therapeutic candidate by analyzing gene expression and drug interactions.
Area of Science:
- Immunology and Molecular Biology
- Genomics and Bioinformatics
Background:
- IgG4-related sialadenitis is a manifestation of IgG4-related disease (IgG4-RD) characterized by IgG4-positive plasma cell infiltration.
- Current treatment options are limited, primarily relying on glucocorticoids.
Purpose of the Study:
- To identify novel therapeutic candidates for IgG4-related sialadenitis.
- To explore transcriptomic profiling and in silico drug repurposing for treatment discovery.
Main Methods:
- RNA sequencing of submandibular gland tissues from patients with IgG4-related sialadenitis and controls.
- Screening of differentially expressed genes against DrugBank for druggable targets.
- Prioritization of candidate drugs based on modulation of disease-associated gene signatures and molecular docking analysis.
Main Results:
- Transcriptomic analysis revealed significant upregulation of immune-related pathways.
- Fostamatinib emerged as a top candidate, targeting kinases including SYK, BTK, and JAK3.
- Molecular docking confirmed favorable binding affinity of fostamatinib, particularly to BTK.
Conclusions:
- Fostamatinib is a promising therapeutic candidate for IgG4-related sialadenitis.
- The study supports a role for the SYK-BTK axis in IgG4-RD pathogenesis.
- Fostamatinib represents a potential alternative treatment to glucocorticoids for IgG4-RD.
